Curosurf

Generic name:poractant alfa
Dosage form: intratracheal suspension
Drug class:Lung surfactants

Medically reviewed by Drugs.com. Last updated on May 1, 2022.

Indications and Usage for Curosurf

Curosurf® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. Curosurf reduces mortality and pneumothoraces associated with RDS.

Curosurf Dosage and Administration

2.1 Important Administration Instructions

For intratracheal administration only.

Curosurf should be administered by, or under the supervision of clinicians experienced in intubation, ventilator management, and general care of premature infants. Before administering Curosurf, assure proper placement and patency of the endotracheal tube. At the discretion of the clinician, the endotracheal tube may be suctioned before administering Curosurf. Allow the infant to stabilize before proceeding with dosing.

Administer Curosurf either:

• Intratracheally by instillation in two divided aliquots through a 5 French end-hole catheter or
• Intratracheally in a single bolus through the secondary lumen of a dual lumen endotracheal tube without interrupting mechanical ventilation.

2.2 Recommended Dosage

The initial recommended dose is 2.5 mL/kg birth weight, administered as one or two aliquots depending upon the instillation procedure [see Dosage and Administration (2.4)].

Up to two repeat doses of 1.25 mL/kg birth weight each may be administered at approximately 12-hour intervals in infants in whom RDS is considered responsible for their persisting or deteriorating respiratory status. The maximum recommended total dosage (sum of the initial and up to two repeat doses) is 5 mL/kg.

2.3 Preparation of the Curosurf Suspension

1. Remove the vial of Curosurf suspension from a refriger...